Teresa Carvalho, MS, science writer —

Too often, cystic fibrosis (CF) patients or their caregivers do not follow proper hygiene procedures when cleaning, disinfecting and storing nebulizers, risking them being a source of lung infections. But proper training can help, a Turkish study reports. Healthcare providers should also be more aware of the potential for poor…

The Cystic Fibrosis Foundation (CFF) has given Beyond Air up to $2.17 million to test its portable inhaled nitric oxide therapy for people with cystic fibrosis (CF) who have chronic, treatment-resistant lung infections caused by non-tuberculous mycobacteria (NTM). This grant award will support a pilot clinical trial to determine…

Pharmaxis announced that a first batch of Bronchitol (mannitol), its dry powder and mucus clearing treatment for cystic fibrosis (CF), is on its way to the U.S. from the company’s manufacturing center in Australia. Recently approved by U.S. Food and Drug Administration (FDA) as a maintenance treatment for…

Two new sites for the extension of a Phase 2b trial testing an immediate release capsule form of MS1819 in treating exocrine pancreatic insufficiency in cystic fibrosis (CF) have opened in Poland and are enrolling patients by invitation. Part of the OPTION 2 study (NCT04375878), these European sites join those already open in…

The Cystic Fibrosis Foundation (CFF) has given Kinnear Pharmaceuticals up to $3 million to conduct the laboratory tests of CSA-131, a potential inhaled treatment of infections in people with cystic fibrosis (CF), that are needed to move it into human trials. CF patients are prone to bacterial lung…

Using bronchoscopy to examine the airways and the surrounding tissues of people with cystic fibrosis, coupled with the collecting of lung fluid through bronchoalveolar lavage (BAL), is safe and a reasonable alternative when sputum samples are not possible, a study reports. Adult patients participating in research reported mild side effects…

The U.S. Food and Drug Administration (FDA) has approved the dry inhalation powder Bronchitol (mannitol) as a maintenance treatment to be used along with other therapies for improving lung function in adults with cystic fibrosis (CF). Bronchitol is currently approved and marketed in Switzerland, Australia, Italy,…

The National Board for Respiratory Care (NBRC) has launched “CHOOSE ONE: Every Breath Counts Campaign,” a fundraising initiative intended to protect and improve the lives of people who need respiratory care, such as those with lung diseases like cystic fibrosis (CF). This year, more than $200,000 will…

Ionis Pharmaceuticals’ investigational inhaled therapy IONIS-ENAC-2.5Rx showed promise in a Phase 1/2a study as a potential new treatment for cystic fibrosis (CF), the company announced, citing trial data. That clinical data showed that ENAC-2.5Rx led to a reduction in the expression of ENaC, a sodium transport…

Twincer, a dry powder inhaler (DPI), was shown to be a more attractive approach for the inhalation of colistin — an antibiotic used to treat lung infections in people with cystic fibrosis (CF) — when compared with a nebulizer, according to a new study. The findings…